Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	5.28B +44.8%
Revenue (ttm)	930.06M -25.5%
Net Income	407.47M -1.6%
EPS	0.53 -1.9%
Shares Out	n/a
PE Ratio	12.95
Forward PE	n/a
Dividend	0.67 (20.69%)
Ex-Dividend Date	Jan 30, 2026

Volume	124,100
Average Volume	178,610
Open	3.260
Previous Close	3.280
Day's Range	3.260 - 3.340
52-Week Range	2.200 - 3.750
Beta	n/a
RSI	48.64
Earnings Date	Apr 30, 2026

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addit...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 3,890
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2025, SGX:T14's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial numbers in CNY